Clinical trials: Sunitinib, completed
Prostate Cancer, Prostatectomy
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
The purpose of this study is to look at blood and tissue samples for changes following the use of Sunitinib malate. Additionally, we would like to find out if the drug, Sunitinib malate, is safe and works in men with prostate…
- Trial name
- NCT00672594
- Testing
- Sunitinib Malate
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Metastatic Melanoma
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005472
- Testing
- sunitinib malate, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Renal Cell Carcinoma, Stage III Renal Cell Cancer
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Conditions
- Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01026337
- Testing
- mutation analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg…
- Trial name
- INTORSECT (NCT00474786)
- Testing
- Sorafenib, temsirolimus (Torisel)
- Where
- 128 sites in United States, Argentina and 18 more
- Volunteers
- 512 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).
- Trial name
- NCT01024920
- Testing
- BIBF 1120, sunitinib
- Where
- 15 sites in Hungary, Poland and 3 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Stromal Tumors
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00716820
- Testing
- SUNITINIB MALATE
- Volunteers
- 472 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumor
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
- Trial name
- NCT01039519
- Testing
- Ganetespib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Synta Pharmaceuticals Corp.
Renal Cell Cancer
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell…
- Trial name
- NCT02684006
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Where
- 270 sites in United States, Australia and 19 more
- Volunteers
- 886 people
- Sponsor
- Pfizer
Differentiated Thyroid Cancer
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine…
- Trial name
- CABOTHYROID (NCT05660954)
- Testing
- Cabozantinib
- Where
- 9 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Breast Neoplasms
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
- Trial name
- NCT00174434
- Testing
- SU011248, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pfizer
Non Small-cell Lung Cancer, Renal-cell Cancer
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
It is well known that substantial interindividual variability of CYP3A4/1A2-phenotype activity is an important contributor to individual differences in the sensitivity to the frequently used tyrosine kinase inhibitors sunitinib…
- Conditions
- Non Small-cell Lung Cancer, Renal-cell Cancer, Gastrointestinal Stroma Tumor
- Trial name
- NCT01402089
- Testing
- Sunitinib, Erlotinib, Midazolam
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Markus Joerger
Pancreatic Cancer
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Primary objective: to evaluate whether the addition of sunitinib prolongates the Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving first-line gemcitabine chemotherapy.
- Trial name
- NCT00673504
- Testing
- Gemcitabine + Sunitinib, Gemcitabine
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 105 people
- Sponsor
- Central European Society for Anticancer Drug Research
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer
Breast Cancer
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
- Trial name
- NCT00887575
- Testing
- Paclitaxel, Carboplatin, Sunitinib
- Where
- 14 sites in United States
- Volunteers
- 54 people
- Sponsor
- SCRI Development Innovations, LLC
GIST
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
This study will examine the effect of BIIB021 on GIST growth and metabolism.
- Trial name
- NCT00618319
- Testing
- BIIB021
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Biogen
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well sunitinib malate works in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer
- Trial name
- NCT00388037
- Testing
- sunitinib malate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Carcinoma
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the immunotherapy, in addition to the approval of…
- Trial name
- INMUNOSUN (NCT03066427)
- Testing
- Sunitinib
- Where
- 9 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Gastrointestinal Stromal Tumors
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
- Trial name
- NCT05381753
- Testing
- Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CStone Pharmaceuticals